Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Core Viewpoint - Xenetic Biosciences, Inc. is focused on advancing innovative immuno-oncology technologies to address difficult-to-treat cancers, highlighting progress in their systemic DNase I program in combination with established cancer therapies [1] Financial Performance - The company reported net proceeds of approximately $3.9 million from an offering in October 2025 [1] - Financial results for the third quarter of 2025 were disclosed, indicating ongoing financial activities [1] Strategic Initiatives - Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners is emphasized, indicating a commitment to building partnerships in the oncology field [1] - The company aims to build a foundation for potentially transformative progress in the oncology treatment paradigm [1]